Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE49.0300
- TODAY'S CHANGE (%)2.4400 (5.2372%)
- Bid / Lots49.9000/ 1
- Ask / Lots50.8400/ 2
- Open / Previous Close46.5900 / 46.5900
- Day Range
- 52 Week Range
- Volume632,362
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 964 | 46.59 |
| 09:34 ET | 700 | 46.15 |
| 09:39 ET | 532 | 46.44 |
| 09:41 ET | 200 | 46.26 |
| 09:52 ET | 496 | 46.49 |
| 09:56 ET | 300 | 46.54 |
| 09:59 ET | 100 | 46.58 |
| 10:01 ET | 100 | 46.645 |
| 10:03 ET | 4331 | 46.46 |
| 10:08 ET | 727 | 46.47 |
| 10:10 ET | 1899 | 46.525 |
| 10:14 ET | 100 | 46.4 |
| 10:15 ET | 100 | 46.31 |
| 10:28 ET | 900 | 46.25 |
| 10:30 ET | 1337 | 46.36 |
| 10:33 ET | 1503 | 46.415 |
| 10:35 ET | 100 | 46.41 |
| 10:42 ET | 1615 | 46.56 |
| 10:48 ET | 1574 | 46.51 |
| 10:57 ET | 100 | 46.3 |
| 11:02 ET | 200 | 46.21 |
| 11:04 ET | 100 | 46.18 |
| 11:08 ET | 200 | 46.29 |
| 11:09 ET | 200 | 46.245 |
| 11:11 ET | 200 | 46.22 |
| 11:18 ET | 100 | 46.04 |
| 11:22 ET | 200 | 46.14 |
| 11:26 ET | 600 | 46.04 |
| 11:27 ET | 100 | 46.0125 |
| 11:31 ET | 242 | 45.97 |
| 11:33 ET | 100 | 45.99 |
| 11:36 ET | 788 | 45.98 |
| 11:38 ET | 100 | 46.02 |
| 11:42 ET | 1997 | 45.79 |
| 11:44 ET | 200 | 45.795 |
| 11:49 ET | 814 | 45.645 |
| 11:54 ET | 100 | 45.635 |
| 11:56 ET | 100 | 45.62 |
| 12:03 ET | 693 | 45.6 |
| 12:05 ET | 453 | 45.585 |
| 12:12 ET | 107 | 45.565 |
| 12:16 ET | 100 | 45.65 |
| 12:23 ET | 100 | 45.56 |
| 12:25 ET | 207 | 45.56 |
| 12:32 ET | 700 | 45.59 |
| 12:34 ET | 150 | 45.67 |
| 12:38 ET | 400 | 45.635 |
| 12:39 ET | 621 | 45.75 |
| 12:41 ET | 866 | 46 |
| 12:43 ET | 200 | 45.99 |
| 12:45 ET | 700 | 46.1 |
| 12:48 ET | 100 | 46.105 |
| 12:52 ET | 118 | 46.12 |
| 12:54 ET | 517 | 46.04 |
| 12:59 ET | 3000 | 46.09 |
| 01:03 ET | 14981 | 46.58 |
| 01:06 ET | 1400 | 46.65 |
| 01:08 ET | 900 | 46.575 |
| 01:14 ET | 357 | 46.455 |
| 01:17 ET | 100 | 46.48 |
| 01:19 ET | 400 | 46.495 |
| 01:21 ET | 1400 | 46.32 |
| 01:24 ET | 10101 | 46.6 |
| 01:28 ET | 100 | 46.505 |
| 01:30 ET | 100 | 46.6 |
| 01:32 ET | 710 | 46.6 |
| 01:33 ET | 873 | 46.605 |
| 01:35 ET | 200 | 46.69 |
| 01:37 ET | 476 | 46.54 |
| 01:39 ET | 16198 | 46.98 |
| 01:42 ET | 2701 | 46.8 |
| 01:46 ET | 1100 | 46.71 |
| 01:48 ET | 100 | 46.83 |
| 01:50 ET | 600 | 46.87 |
| 01:51 ET | 724 | 46.92 |
| 01:53 ET | 3492 | 46.8799 |
| 01:55 ET | 550 | 47.02 |
| 01:57 ET | 2389 | 47.085 |
| 02:00 ET | 900 | 47.155 |
| 02:02 ET | 1778 | 47.07 |
| 02:04 ET | 1668 | 47.22 |
| 02:06 ET | 530 | 47.185 |
| 02:08 ET | 1050 | 47.31 |
| 02:09 ET | 300 | 47.18 |
| 02:11 ET | 1081 | 47.235 |
| 02:15 ET | 2535 | 47.48 |
| 02:18 ET | 2245 | 47.48 |
| 02:20 ET | 710 | 47.48 |
| 02:22 ET | 600 | 47.475 |
| 02:26 ET | 870 | 47.52 |
| 02:29 ET | 600 | 47.55 |
| 02:31 ET | 800 | 47.525 |
| 02:33 ET | 2063 | 47.575 |
| 02:36 ET | 1670 | 47.65 |
| 02:38 ET | 627 | 47.71 |
| 02:40 ET | 5234 | 47.87 |
| 02:42 ET | 2200 | 48.075 |
| 02:44 ET | 1000 | 47.93 |
| 02:45 ET | 3332 | 48.03 |
| 02:47 ET | 700 | 47.99 |
| 02:49 ET | 11880 | 47.995 |
| 02:51 ET | 1900 | 48.12 |
| 02:54 ET | 1700 | 48.04 |
| 02:56 ET | 1800 | 48.2 |
| 02:58 ET | 2639 | 48.2 |
| 03:00 ET | 1901 | 48.18 |
| 03:02 ET | 2047 | 48.11 |
| 03:03 ET | 4220 | 48.44 |
| 03:05 ET | 900 | 48.36 |
| 03:07 ET | 1300 | 48.39 |
| 03:09 ET | 300 | 48.41 |
| 03:12 ET | 1373 | 48.39 |
| 03:14 ET | 2900 | 48.51 |
| 03:16 ET | 2382 | 48.65 |
| 03:18 ET | 1600 | 48.78 |
| 03:20 ET | 2675 | 48.71 |
| 03:21 ET | 5489 | 48.895 |
| 03:23 ET | 711 | 48.86 |
| 03:25 ET | 738 | 48.775 |
| 03:27 ET | 4142 | 48.85 |
| 03:30 ET | 925 | 48.88 |
| 03:32 ET | 5554 | 48.91 |
| 03:34 ET | 3804 | 48.845 |
| 03:36 ET | 4502 | 49 |
| 03:38 ET | 1521 | 48.85 |
| 03:39 ET | 31594 | 48.765 |
| 03:41 ET | 1400 | 48.88 |
| 03:43 ET | 3304 | 48.935 |
| 03:45 ET | 1557 | 49.06 |
| 03:48 ET | 2096 | 49.035 |
| 03:50 ET | 3285 | 48.96 |
| 03:52 ET | 5398 | 48.955 |
| 03:54 ET | 4149 | 48.92 |
| 03:56 ET | 13457 | 48.86 |
| 03:57 ET | 11324 | 48.86 |
| 03:59 ET | 167759 | 49.03 |
Sep 19, 2024
DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 9:18AM ET on Thursday Sep 19, 2024 by Dow Jones
9:18AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 11, 2024
DJ Agios Gets FDA Orphan Designation for Tebapivat in Myelodysplastic Syndromes, from 7:28AM ET on Wednesday Sep 11, 2024 by Dow Jones
7:28AM ET on Wednesday Sep 11, 2024 by Dow JonesAgios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS), from 7:00AM ET on Wednesday Sep 11, 2024 by Dow Jones
7:00AM ET on Wednesday Sep 11, 2024 by Dow Jones
Sep 5, 2024
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024, from 7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 2.7B | -7.6x | --- |
IDEAYA Biosciences Inc | 2.7B | -13.9x | --- |
Celldex Therapeutics Inc | 2.7B | -13.1x | --- |
Janux Therapeutics Inc | 2.5B | -52.3x | --- |
Vera Therapeutics Inc | 2.6B | -20.4x | --- |
Geron Corp | 2.8B | -12.5x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
|---|---|
Revenue (TTM) | $31.3M |
Shares Outstanding | 56.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-6.49 |
Book Value | $14.50 |
P/E Ratio | -7.6x |
Price/Sales (TTM) | 84.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,293.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
